Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy

This study is testing a technology called KIM (Kilovoltage Intrafraction Monitoring) that tracks a radio-opaque marker (a visible substance previously placed in the liver during a prior procedure) during radiation therapy for liver cancer — to better target the tumor and avoid harming healthy tissue. **You may be eligible if...** - You have liver cancer and are receiving (or have received) stereotactic ablative body radiotherapy (SABR) at a participating site - A radio-opaque contrast agent (such as Lipiodol or DC Bead LUMI) is visible on your radiation planning CT scan and will be in the imaging field during treatment - You are 18 years of age or older **You may NOT be eligible if...** - You are under 18 years of age - The required image data is not available or is in an incompatible format Talk to your doctor to see if this trial is right for you.